Phase 1, single center, open-label study to establish a safe dose (ie, number of cells/kg) of autologous iC9.GD2.CAR.IL-15 T-cells in pediatric patients with
relapsed or refractory neuroblastoma.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2020 Healio All Rights Reserved.